Telmisartan reverses hepatic steatosis via PCK1 upregulation: A novel PPAR-independent mechanism in experimental models of MASLD

This publication has 59 references indexed in Scilit:

• Pemafibrate abrogates SLD in a rat experimental dietary model, inducing a shift in fecal bile acids and microbiota composition
  Biomedicine & Pharmacotherapy, 2024
• Role of Angiotensin II in Non-Alcoholic Steatosis Development
  Archives of Medical Research, 2024
• ChREBP‐driven DNL and PNPLA3 Expression Induced by Liquid Fructose are Essential in the Production of Fatty Liver and Hypertriglyceridemia in a High‐Fat Diet‐Fed Rat Model
  Molecular Nutrition & Food Research, 2022
• Nutrition and Nonalcoholic Fatty Liver Disease
  Gastroenterology Clinics of North America, 2020
• Telmisartan and/or chlorogenic acid attenuates fructose-induced non-alcoholic fatty liver disease in rats: Implications of cross-talk between angiotensin, the sphingosine kinase/sphingoine-1-phosphate pathway, and TLR4 receptors
  Biochemical Pharmacology, 2019
• Fibrosis Progression in Nonalcoholic Fatty Liver vs Nonalcoholic Steatohepatitis: A Systematic Review and Meta-analysis of Paired-Biopsy Studies
  Clinical Gastroenterology and Hepatology, 2015
• Angiotensin II type 1 receptor-independent beneficial effects of telmisartan on dietary-induced obesity, insulin resistance and fatty liver in mice
  Diabetologia, 2010
• Spermine and spermidine mediate protection against oxidative damage caused by hydrogen peroxide
  Amino Acids, 2007
• 435‐bp liver regulatory sequence in the liver fatty acid binding protein (L‐FABP) gene is sufficient to modulate liver regional expression in transgenic zebrafish
  Developmental Dynamics, 2003
• A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding
  Analytical Biochemistry, 1976